Anti-ADAR2 antibody

Rs. 50,211.00
SKU stj91484

General Information

Product name Anti-ADAR2 antibody
Short Description
Description Rabbit polyclonal to ADAR2.
Applications WB,IHC,ELISA
Dilution range WB 1:500-1:2000IHC 1:100-1:300ELISA 1:20000
Protein Name Anti-ADAR2 antibody
Immunogen Synthesized peptide derived from human ADAR2
Storage Instruction Store at -20°C, and avoid repeat freeze-thaw cycles.
Type of Usage For Research Use Only (RUO).

Product Properties

Host Rabbit
Clonality Polyclonal
Reactivity Human,Mouse,Rat
Conjugation Unconjugated
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Isotype IgG
Formulation Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Target

Gene ID
Gene Symbol
Molecular Weight 80 kDa
Database Links
Alternative Names Double-stranded RNA-specific editase 1 antibody
RNA-editing deaminase 1 antibody
RNA-editing enzyme 1 antibody
dsRNA adenosine deaminase antibody
DRADA2 antibody
RED1 antibody
Function Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis.
Cellular Localization Nucleus. Nucleus, nucleolus. Shuttles between nucleoli and the nucleoplasm.
Tissue Specificity Highly expressed in brain and heart and at lower levels in placenta. Fair expression in lung, liver and kidney. Detected in brain, heart, kidney, lung and liver (at protein level). Isoform 5 is high expressed in hippocampus and colon. Isoform 5 is expressed in pediatric astrocytomas and the protein has a decreased RNA-editing activity. The decrease in RNA editing correlates with the grade of malignancy of the tumors, with the high grade tumors showing lower editing is seen.
Swiss-Prot Key

 

You recently viewed

Clear recently viewed